Psychedelics

Marijuana Company of America, Inc. (OTC: MCOA) ("the Company"), a diversified holding company with operations and investments throughout the cannabis industry, today announced that its new wholly owned subsidiary cDistro, has reached an agreement with Silo Wellness, Inc. (CSE: SILO) (OTC: SILFF) (FRA: 3K70) to distribute Marley One, the first global functional mushroom brand, in collaboration with the Bob Marley Family.

Silo Wellness, a leading global psychedelics company, chose cDistro as one of its first distributors to launch Marley One, the first global functional and psychedelic mushroom consumer brand.

The initial product offering will include a range of functional mushroom tinctures, including species such as cordyceps, lion's mane, chaga, reishi and turkey tail that offer a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement. Silo has also announced that it intends to launch a psychedelic mushroom product line under the Marley name later this year, to be followed by additional functional mushroom products including gummies, capsules and cosmetics.

"We believe it is important to be a leader in providing access to newer product categories, and we are honored to distribute and provide access to Marley One, the first global functional mushroom brand, in collaboration with the Bob Marley Family," said Ron Russo, cDistro's President. "The Marley family name is an iconic part of our history and we're thrilled to bring these exciting new products into our fast growing distribution portfolio. We have already commenced our marketing efforts to introduce and distribute Marley One, in collaboration with Silo Wellness and the Bob Marley Family. This distribution agreement and other new initiatives, epitomizes our growth and plans for continued growth and expansion." "This represents a new beginning for Marijuana Company of America as it begins its quest to diversify its product base and begin significant strides to become a proactive leader in the Cannabis industry," said Jesus Quintero, CEO of Marijuana Company of America, Inc.

Silo's CEO, Douglass Gordon, stated, "We are pleased to have chosen cDistro as one of our initial distributors and we expect that as our global functional mushroom brands continues to develop that we will become the world's first global functional and psychedelic mushroom brand, guided by a vision to help people achieve healthier lifestyle."

About Marijuana Company of America, Inc. (OTC: MCOA)

Marijuana Company of America is a diversified holding company with operations and investments throughout the cannabis industry. MCOA focuses on acquisitions, as well as sales and marketing efforts of its wholly owned subsidiaries cDistro and hempsmart™ premium brand of hemp-based CBD (legal cannabidiol) products.

About cDistro

cDistro (Retail Service / Wholesale Prices) distributes CBD brands, along with smoke and vape shop related products to wholesalers, c-stores, specialty retailers, and consumers in North America.

Forward-Looking Statements

This news release contains "forward-looking statements," which are not purely historical and may include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs, and results of new business opportunities and words such as "anticipate," "seek," "intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q, and other periodic reports filed from time to time with the Securities and Exchange Commission.

For more information, please visit www.marijuanacompanyofamerica.com or visit www.sec.gov.

Contact
info@marijuanacompanyofamerica.com
info@mcoainvestments.com
888-777-4362


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Silo Wellness

Silo Wellness


Keep reading...Show less
Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia

Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into an exclusive agreement with iNGENū Pty Ltd. ("iNGENū"), an Australian based Contract Research Organization (CRO), to design and conduct three or more clinical trials evaluating Lobe's proprietary psilocin analogues L-130 or L-131.

Philip Young, CEO of Lobe Sciences stated, "We are extremely happy to have partnered with iNGENū as we move our proprietary stable psilocin products into human clinical trials. iNGENū is an industry leading, full service CRO providing end-to-end services for companies developing cannabinoid and psychedelic drugs. We evaluated CRO's in multiple geographies and chose iNGENu as their core values match ours and our commitment to discovering transformational therapies for multiple Central Nervous System diseases and trauma."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Optimi Health Unveils Canada's First Natural Therapeutic Psilocybin Product For Approved Patients

Optimi Health Unveils Canada's First Natural Therapeutic Psilocybin Product For Approved Patients

Blue Serenity brings science and compassion together, will cement Thomas Hartle's legacy as a Canadian psychedelic icon

Optimi and Hartle to host press conference today at 1:00 PM EST

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Nirvana Life Sciences

Nirvana Appoints New Chief Financial Officer

Nirvana Life Sciences Inc., (CSE:NIRV) ("Nirvana" or the "Company") a Canadian based life sciences company aimed at developing non-addictive chronic pain and addiction treatment products announces that Connie Hang has resigned as Chief Financial Officer of the Company. The Company thanks Ms. Hang for her work as CFO over the last 2 years, she will continue serving the Company as a Contractor.

Annie Storey, CPA, CA, BBA has been appointed as Chief Financial Officer, effective immediately. Ms. Storey, a director of the Company since 2017, brings over 25 years' experience in accounting, auditing, financial reporting and corporate services for Canadian and US public companies in the mining, entertainment and biotechnology sectors.

Keep reading...Show less
Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle

Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for transformational human experiences, is pleased to announce that it has entered into a partnership with psilocybin patient advocate, Thomas Hartle. The parties have agreed to produce a Canadian-grown and harvested natural therapeutic psilocybin product for use by approved patients.

"Honouring Thomas's incredible optimism and appreciation for life with his own natural, Canadian-grown psilocybin product is something we will cherish as a company forever," said Bill Ciprick, CEO of Optimi Health. "We share Thomas's energy and passion for creating the perfect psilocybin experience, and we look forward to providing a vital service to Special Access Program patients while further demonstrating to regulators that psychedelic-assisted therapies can be integrated into our existing healthcare framework."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

-

Highlights:
  • Kabir Nath appointed as Chief Executive Officer
  • Phase III program submitted to FDA and under review
  • COMP360 phase II study in anorexia nervosa launched
  • Cash position at 30 June 2022 of $207.2 million
  • Conference call today at 8:00am ET (1:00pm UK)

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2022 and gave an update on recent progress across its business.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Morgan Stanley Positive in First Psychedelics Research Report

Morgan Stanley Positive in First Psychedelics Research Report

Morgan Stanley (NYSE:MS) has shared its first official commentary on the psychedelics industry.

The concept of investing in psychedelic medicine received a legitimate vote of confidence of sorts after the well-established banking firm released an introductory study evaluating the potential attached to the sector.

The research is intended to offer an initial look at the psychedelics investment proposal.

Keep reading...Show less

Latest Press Releases

Related News

×